

CHOROIDEREMIA RESEARCH FOUNDATION INVITES PROPOSALS FOR THE 2024 RANDY WHEELOCK RESEARCH AWARD

Proposals related to finding a cure for a rare inherited retinal disease are due by March 31, 2024

SPRINGFIELD, MA, UNITED STATES,
February 1, 2024 /EINPresswire.com/ --

The Choroideremia Research
Foundation (CRF) is pleased to

welcome proposal submissions for the

5th Annual Randy Wheelock Research Award. The award designation recognizes emerging scientists and research professionals working on choroideremia (CHM) or related vision loss issues. Eligible recipients will be either doctoral or post-doctoral candidates and professionals, and awards will be granted in the amount of \$50,000.

Introduced in 2020, the Randy Wheelock Award celebrates the decades-long advocacy of its namesake to find treatment or a cure for CHM. As CRF's Chief Advisor for Research and Therapy Development, Randy was an integral part of the organization's achievements over the years. He collaborated with researchers and other rare disease groups to leverage assets and scientific knowledge in search of treatment options and a cure for CHM.

CRF recognizes a range of study aims when evaluating proposals. Previous award recipients include:

Kim Edwards (2020), Cellular and Molecular Pathology program at University of Wisconsin-Madison

"Identifying the Function of REP-1 Protein in Retina (RPE/Photoreceptors) and Non-Retina Tissues."

Dr. Cynthia Qian (2021), Ophthalmologist at the Department of Ophthalmology, Centre hospitalier universitaire Sainte-Justine

"Characterizing the phenotypical findings in female carriers with confirmed CHM mutation using multimodal imaging and functional test."



Choroideremia
RESEARCH FOUNDATION

CRF has funded approximately \$5 million in research studies during its 23-year history.

Bhanu P. Telugu, PhD (2022), Associate Professor at the Division of Animal Sciences at the University of Missouri in Columbia, Founder, President and Chief Scientific Officer of RenOVate Biosciences, Inc.

“A Novel Porcine Pre-Clinical Model for Choroideremia Research”

Luisa de Lemos, PhD (2023), Postdoctoral Research at the Champalimaud Foundation, Portugal
“Pathways of Retinal Pigment Epithelium Degeneration in Choroideremia”

For more information about applying, please visit the Apply for Funding page on curechm.org/research. Proposals are due March 31, 2024.

About Choroideremia

Choroideremia (CHM) is a rare inherited form of blindness affecting approximately 1 in 50,000 people. Due to its x-linked inheritance pattern males are most severely affected with females usually experiencing much milder visual impairment. Symptoms begin in early childhood with night blindness and restriction of visual field being the earliest noticeable effects, eventually progressing to complete blindness. An estimated 6,000 people in the United States and 10,000 in the European Union are impacted by Choroideremia. There are currently no approved treatments for Choroideremia. For more information, visit curechm.org/choroideremia

About the Choroideremia Research Foundation Inc.

The Choroideremia Research Foundation was founded in 2000 as an international fundraising and patient advocacy organization to stimulate research on CHM. Since its inception, the CRF has provided approximately \$5 million in research awards and is the largest financial supporter of CHM research worldwide. Research funded by the CRF has led to the development of a CHM animal model, the pre-clinical production of gene therapy vectors currently in clinical trials, and the CRF Biobank which stores tissue and stem cell samples donated by CHM patients. For more information, visit curechm.org

Kathleen Wagner

Choroideremia Research Foundation Inc

+1 800-210-0233

kathiwagner@curechm.org

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[TikTok](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/685295278>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.